Q&A on the Johnson & Johnson COVID-19 vaccine with Mona Chitre, PharmD, Chief Pharmacy Officer and Vice President of Clinical Strategy and Innovation at Excellus BlueCross BlueShield

Posted on March 9, 2021

Dr. Chitre leads Excellus BlueCross BlueShield’s pharmacy strategy and is responsible for driving affordability, innovation and operational excellence. She completed her undergraduate and graduate training at Rutgers University and her post-doctoral primary care residency at the Buffalo VA Medical Center in Buffalo, New York.

Q: Dr. Chitre, the Johnson & Johnson (J&J) vaccine is the third COVID-19 vaccine being distributed in the U.S. Is it safe? Why do we need a third vaccine option?
A: All vaccines have the same goal – to protect us. The J&J vaccine was tested thousands of times to ensure safety and is authorized for use in the U.S. It’s important that everyone who wants the COVID-19 vaccine can receive it. In addition to the Moderna and Pfizer-BioNTech vaccines, the J&J vaccine is another way to help increase protection against the virus that causes COVID-19. Since all three vaccines are safe, the best vaccine is the one you have access to.

Q: How does the J&J vaccine differ from Moderna’s and Pfizer-BioNTech’s?
A: The J&J vaccine is a single dose which offers maximum protection quicker than Moderna’s and Pfizer-BioNTech’s vaccines. The J&J vaccine has proven to be 66% effective at preventing moderate to severe cases of COVID-19. With all three vaccine options, no fragment of the live virus is in the vaccine so the vaccine itself cannot make you sick with COVID-19.

Q: Should we be concerned with a less effective rate?
A: No, there is no need to be concerned. The only way to accurately compare the effectiveness of these vaccines is by direct comparison in head-to-head clinical trials, which did not happen across the three vaccine options. Testing took place in different regions, at different points in time, and with varying COVID-19 occurrences. It is best not to compare the effective rates between the vaccines.

The data proves that the J&J vaccine is 85% effective against severe COVID-19 cases, and 100% effective at preventing death from COVID-19. Based on the data, the J&J vaccine is a very safe and effective option.

Q: There is mention of a booster vaccine to help protect against the COVID-19 variants. What information is known or suggested about this?

A: Scientists are currently looking into if a booster dose is needed to address variants. It is emerging science at this time, but it is still recommended that you get your vaccine as soon as it is available for you.

Q: We know that vaccines were given to high-risk groups first. The data suggests that the number of deaths in nursing homes is going down by more than 60%. Do you feel this is because of the vaccine?
A: Absolutely. Nursing home residents were among the first people to receive the vaccine. The data shows how powerful the vaccines are against the virus, which is encouraging to hear. Reports like these make me so hopeful as the vaccines continue to rollout. I’m excited for my children to be reunited with their grandparents. I’m optimistic about the future.

Other Member News

CNY Biotech Accelerator - 2026 Events / Pitch Opportunity
January 14, 2026

CNY Biotech Accelerator - 2026 Events / Pitch Opportunity

The Central New York Biotech Accelerator is hosting or partnering on exciting events and has a full complement of virtual sessions schedu

January 14, 2026

Oswego Health Offers After-Hours Urology Clinic to Better Serve Busy Patients

This new clinic offers convenient evening appointments for patients experiencing ongoing or complex urologic conditions.

Oswego Health
January 14, 2026

Oswego Health Employees Raise More Than $78,000 to Support Patient Comfort and Care

A total of 492 employees participated, exceeding the participation goal of 375 employees and surpassing last year’s fundraising total.

Excellus BCBS
January 14, 2026

2026 Health Equity Innovation Awards

At Excellus BlueCross BlueShield the health of our communities is at the center of everything we do.

United Way of Central New York Appoints Carrie Large as new President and CEO
January 14, 2026

United Way of Central New York Appoints Carrie Large as new President and CEO

Large will join the United Way of Central New York after most recently serving as the executive director of the Friends of the Rosamond Gifford Zoo.

January 13, 2026

Autism Acceptance Walk

This event is packed with fun, games, prizes, a photo booth and more.

J Rossi pic
January 13, 2026

Modern Advocacy Named to City & State's 2026 Who’s Who in Political Consulting

City & State’s Who’s Who in Political Consulting & Communications puts a spotlight on the PR and political comms pros who are on the front lines of the biggest campaigns in New York and beyond.

MHEDA MVP Award
January 13, 2026

Thompson & Johnson Earns MHEDA MVP Award for 10th Consecutive Year

The MVP Award is one of the most coveted honors in the material handling industry.

Barton & Loguidice Founders from 1961 (Left to Right) Frank Loguidice, James Clyde, Ken Brown, Edwin Barton
January 12, 2026

Barton & Loguidice Celebrates 65 Years of Service, Growth and Innovation

The firm is commemorating more than six decades of service to clients and communities across the region.